S633
Clinical – Head & neck
ESTRO 2026
1 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. 2 State Key Laboratory of Oncology in South China, Sun Yat- sen University Cancer Center, Guangzhou, China. 3 Department of Radiation Oncology, Shenzhen People's Hospital, Shenzhen, China. 4 Hospital of Stomatology, Guanghua School of Stomatology, Guangzhou, China. 5 Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. 6 Yuebei People's Hospital Affiliated to the Medical College of Shantou University, Shantou University, Shantou, China Purpose/Objective: To evaluate the efficacy and safety of nimotuzumab combined with benmelstobart and platinum-based doublet neoadjuvant therapy in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), with the primary endpoint of Objective This was a prospective phase II single-arm multicenter trial. Eligible patients had stage Ⅲ - Ⅳ b HNSCC (AJCC 8th edition) with ECOG PS 0-1. Treatment included nimotuzumab 400mg (Q3W, 2 cycles) + benmelstobart 1200mg (Q3W, 2 cycles) + platinum-based doublet chemotherapy (Q3W, 2 cycles). Efficacy was assessed by RECIST 1.1, safety by NCI-CTC version 5.0. Results: Response Rate (ORR). Material/Methods: A total of 30 patients were screened: 24 continued treatment, 6 discontinued. Median age was 56 years (range: 35-68 years), 89.66% male. Median follow-up was 65 days (range: 47-257 days). Primary endpoint ORR was 100%, all being Partial Response (PR). For safety (15 assessable patients), the most common adverse events were anemia (14/15) and hypoalbuminemia (12/15). Grade 3-4 adverse events included leukopenia, thrombocytopenia, and oral mucositis. No unexpected severe adverse events occurred; overall safety was manageable. Conclusion: Nimotuzumab plus benmelstobart and platinum- based doublet neoadjuvant therapy showed excellent ORR (100%) in locally advanced HNSCC with a median follow-up of 65 days. Treatment-related adverse events were predictable and controllable, supporting further investigation. Keywords: HNSCC, nimotuzumab,benmelstobart
57.58%, 80.04% and 71.1%, respectively. Univariate and multivariate analysis showed that T stage (p ＜ 0.001, HR=1.655) and N stage (p=0.002, HR=1.324) were significantly associated with 10-years OS. Based on the different T and N constitution, we compared the 7 subgroups in TNM-9. The 10-year survival results revealed the patients could be stratified into three subgroups: low-risk group (T1N3, T2N3: 76.7%, 72.9%, p=0.737), intermediate-risk group (T3N3, T4N0, T4N1: 61.5%, 63.6%, 60.0%, p=0.821) and high-risk group (T4N2,T4N3: 46.3%, 39.0%, p=0.38). It showed significant differences among the low-risk, intermediate-risk, and high-risk groups for 10-year OS (74.4%, 62.3%, 43.7%, p<0.001), PFS (67.5%, 60.7%, 43.1%, p<0.001), LRFS (84.2%, 71.2%, 64.9%, p=0.048) and DMFS (72.0%, 72.0%, 49.5%, p<0.001),
respectively. Conclusion:
The stage III NPC patients based on TNM-9 staging system encompasses a heterogeneously prognostic population. Our novel subgroups based on different T and N constitution could effectively stratifies this cohort into three distinct groups. This new stratification might derive the substantial modification of treatment strategy for better prognosis in the further research. References: 1. Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity- modulated radiotherapy. Cancer. 20162. Lee AW, Ng WT, Pan JJ, et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 20193. Tsai TY, Chou YC, et al. The prognostic value of radiologic extranodal extension in nasopharyngeal carcinoma: Systematic review and meta-analysis. Oral Oncol. 20214. Liang W, Shen G, et al. Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment. Chin J Cancer. 2016 Keywords: NPC, TNM-9 system, Prognostic stratification Digital Poster 3749 A phase II single-arm multicenter study of nimotuzumab plus benmelstobart and platinum- based doublet neoadjuvant therapy for locally advanced HNSCC Yuanyuan Chen 1,2 , Ying WANG 1,2 , Ying Piao 3 , Yuchuan Zhou 1,2 , Dikan WANG 4 , Zihuang Li 3 , Gang Xu 3 , Yujie Liang 4 , Yanfeng Cheny 2,5 , Shuzhen Lai 6 , Lixia Lu 1 , Guiqing Liao 4
Proffered Paper 3759
Incidence and survival of supraglottic squamous cell carcinoma in Denmark, 1986–2020: a national population-based DAHANCA study of 3154 patients Janne M Pedersen 1,2 , Jan Alsner 2 , Nina M Lyhne 3 , Jesper G Eriksen 2 , Thomas Kjærgaard 1 , Jens Overgaard 2
Made with FlippingBook - Share PDF online